{
    "name": "levonorgestrel intrauterine",
    "comment": "Rx",
    "other_names": [
        "Mirena",
        "Skyla",
        "Liletta",
        "Kyleena"
    ],
    "classes": [
        "Progestins"
    ],
    "source": "https://reference.medscape.com/drug/mirena-skyla-levonorgestrel-intrauterine-342780",
    "pregnancy": {
        "common": [
            "Contraindicated in pregnancy or suspected pregnancy",
            "If a females becomes pregnant with IUD in place, risk of ectopic pregnancy is increased as well as miscarriage, sepsis, premature labor, and premature delivery",
            "Isolated cases of virilization of external genitalia of female fetus following exposure to levonorgestrel during pregnancy with a levonorgestrel intrauterine device in place",
            "Remove IUD, if possible, if pregnancy occurs in a woman using IUD",
            "If a woman becomes pregnant with levonorgestrel intrauterine device in place and the woman chooses not to have it removed or can’t be removed, advise her of reports of virilization of the female fetus following local exposure to levonorgestrel during pregnancy; closely follow pregnancy"
        ],
        "specific": [
            {
                "type": "Female and male reproductive potential",
                "description": [
                    "Probability to conceive within 12 months after removal of intrauterine system reported to be approximately 77%"
                ]
            }
        ]
    },
    "lactation": {
        "common": [
            "Published studies report presence of LNG in human milk",
            "Small amounts of womens-health-reproduction#progestins (~0.1% of the total maternal doses) were detected in the breast milk of nursing mothers who used other LNG-releasing IUSs, resulting in exposure of LNG to the breastfed infants",
            "There are no reports of adverse effects in breastfed infants with maternal use of progestin-only contraceptives",
            "Isolated cases of decreased milk production have been reported with a LNG-releasing IUS"
        ]
    },
    "warnings": {
        "black_box_warning": {
            "common": [],
            "specific": []
        },
        "contraindicators": {
            "common": [
                "Pregnancy or suspicion of pregnancy; cannot be used for postcoital contraception (emergency contraception)",
                "Congenital or acquired uterine anomaly including fibroids if they distort the uterine cavity ",
                "Acute pelvic inflammatory disease or a history of pelvic inflammatory disease unless there has been a subsequent intrauterine pregnancy",
                "Postpartum endometritis or infected abortion in the past 3 months",
                "Known or suspected uterine or cervical neoplasia",
                "Known or suspected breast cancer or other progestin-sensitive cancer, now or in the past",
                "Uterine bleeding of unknown etiology",
                "Untreated acute cervicitis or vaginitis, including bacterial vaginosis or other lower genital tract infections until infection is controlled",
                "Acute liver disease or liver tumor (benign or malignant)",
                "Conditions associated with increased susceptibility to pelvic infections ",
                "Previously inserted intrauterine device (IUD) that has not been removed ",
                "Hypersensitivity to any component of this product"
            ],
            "specific": []
        },
        "cautions": {
            "common": [
                "Evaluate women for ectopic pregnancy; ~50% of pregnancies that occur with IUD are likely to be ectopic; also consider possibility of ectopic pregnancy in case of lower abdominal pain, especially in association with missed menses or if an amenorrheic woman starts bleeding",
                "Severe infection, including group A streptococcal sepsis reported",
                "Bleeding pattern alterations may occur, including amenorrhea, infrequent bleeding, prolonged bleeding, or irregular bleeding",
                "Perforation may occur, most often during insertion; an interim analysis from a large postmarketing safety study shows an increased risk of perforation in lactating women; perforation risk may be increased in women with fixed retroverted uteri, and during the postpartum period; perforation may also occur at any time during IUS use; perforation may reduce contraceptive efficacy and result in pregnancy; this may be associated with severe pain and continued bleeding",
                "Inform women who use product about recognizing signs and symptoms of ectopic pregnancy and promptly reporting them to their healthcare professional, and about the associated risks of ectopic pregnancy (eg, loss of fertility)",
                "Exclude underlying endometrial pathology (eg, polyps or cancer) prior to insertion of device in women with persistent or uncharacteristic bleeding; irregular bleeding/spotting is common during first months of use and may preclude adequate assessment after insertion",
                "If the threads are not visible or are significantly shortened, they may have broken or retracted into cervical canal or uterus; consider possibility that IUS may have been displaced, (for example, expulsed or perforated the uterus); exclude pregnancy and verify location of device by an appropriate diagnostic method",
                "Women who currently have or have had breast cancer, or have a suspicion of breast cancer, should not use hormonal contraception, because some breast cancers are hormone-sensitive",
                "Product not intended for use in menopausal women",
                "Women with symptomatic actinomycosis should have device removed and should receive antibiotics"
            ],
            "specific": [
                {
                    "type": "Pelvic inflammatory disease",
                    "description": [
                        "Pregnant women whose device cannot be removed or if patient chooses not to have it removed, increases risk of miscarriage, sepsis, premature labor, and premature delivery; advise patient of isolated reports of virilization of the female fetus following local exposure to drug during pregnancy with an IUS in place",
                        "Prenatal care should include counseling about these risks and instructions to immediately report any flu-like symptoms, fever, chills, cramping, pain, bleeding, vaginal discharge or leakage of fluid, or any other symptom that suggests complications of the pregnancy",
                        "After initiation of antibiotic treatment, the IUS may be removed or kept in place; the patient should continue to receive antibiotic treatment according to current recommendations and should have close clinical follow-up; guidelines for PID or endometritis treatment are available from the Centers for Disease Control (CDC), Atlanta, Georgia",
                        "If patient opts for ongoing IUS contraception, patient may forego immediate removal of the device after initiation of antibiotic treatment; however, the patient should have close clinical follow-up",
                        "If no clinical improvement occurs within 48–72 hours of initiating treatment, IUS removal is appropriate with continued antibiotic therapy, as indicated",
                        "PID may be asymptomatic but still result in tubal damage and its sequelae",
                        "Promptly examine users with complaints of lower abdominal or pelvic pain, odorous discharge, unexplained bleeding, fever, genital lesions or sores; remove device in cases of recurrent endometritis or PID, or if an acute pelvic infection is severe or does not respond to treatment",
                        "IUDs have been associated with an increased risk of PID, most likely due to organisms being introduced into the uterus during insertion",
                        "PID is often associated with a sexually transmitted infection (STI), and this therapy does not protect against STI; risk of PID is greater for women who have multiple sexual partners, and also for women whose sexual partner(s) have multiple sexual partners; other risk factors for these infections include unprotected sex and acquired immune deficiency syndrome (AIDS)",
                        "Women who have had PID are at increased risk for a recurrence or re-infection; in particular, ascertain whether woman is at increased risk of infection (for example, leukemia, acquired immune deficiency syndrome [AIDS], intravenous drug abuse)",
                        "Following a diagnosis of PID, or suspected PID, obtain bacteriologic specimens and initiate antibiotic therapy promptly; removal of device after initiation of antibiotic therapy is usually appropriate"
                    ]
                },
                {
                    "type": "Perforation",
                    "description": [
                        "Perforation may occur, most often during insertion; an interim analysis from a large postmarketing safety study shows an increased risk of perforation in lactating women",
                        "Risk of uterine perforation is increased in women who have recently given birth, and in women who are breastfeeding at time of insertion and during postpartum period; risk of perforation may be increased if device is inserted when the uterus is fixed, retroverted or not completely involuted",
                        "Perforation may also occur at any time during IUS use and may reduce contraceptive efficacy and result in pregnancy; this may be associated with severe pain and continued bleeding",
                        "If perforation occurs, locate, and remove device; surgery may be required; delayed detection or removal of device in case of perforation may result in migration outside uterine cavity, adhesions, peritonitis, intestinal perforations, intestinal obstruction, abscesses and erosion of adjacent viscera"
                    ]
                },
                {
                    "type": "Bleeding pattern alterations",
                    "description": [
                        "Device can alter the bleeding pattern and result in spotting, irregular bleeding, heavy bleeding, oligomenorrhea and amenorrhea; during first 3–6 months of use, number of bleeding and spotting days may be higher and bleeding patterns may be irregular",
                        "Thereafter number of bleeding and spotting days usually decreases but bleeding may remain irregular; if bleeding irregularities develop during prolonged treatment, take appropriate diagnostic measures to rule out endometrial pathology",
                        "Amenorrhea develops in approximately 20% of device users by one year",
                        "Consider possibility of pregnancy if menstruation does not occur within six weeks of onset of previous menstruation; once pregnancy has been excluded, repeated pregnancy tests are generally not necessary in amenorrheic women unless indicated, for example, by other signs of pregnancy or by pelvic pain",
                        "In most women with heavy menstrual bleeding, the number of bleeding and spotting days may also increase during initial months of therapy but usually decrease with continued use; the volume of blood loss per cycle progressively becomes reduced"
                    ]
                },
                {
                    "type": "Expulsion",
                    "description": [
                        "Partial or complete expulsion of intrauterine device may occur resulting in loss of contraceptive protection; expulsion may be associated with symptoms of bleeding or pain, or it may be asymptomatic and go unnoticed",
                        "Drug typically decreases menstrual bleeding over time; an increase of menstrual bleeding may be indicative of an expulsion",
                        "Consider further diagnostic imaging, such as x-ray, if expulsion is suspected based on ultrasound",
                        "Risk of expulsion is increased with insertions immediately after delivery and appears to be increased with insertion after second-trimester abortion based on limited data; in a large postmarketing safety study conducted in US, risk of expulsion was lower with breastfeeding status",
                        "Remove a partially expelled device; if expulsion has occurred, a new device can be inserted any time the provider can be reasonably certain the woman is not pregnant",
                        "A 5-year expulsion rate of 3.5% (59 out of 1,690 subjects) reported in clinical trials; delay insertion a minimum of 4 weeks or until uterine involution complete following a delivery or a second-trimester abortion"
                    ]
                },
                {
                    "type": "Septic abortion",
                    "description": [
                        "If a patient becomes pregnant with an IUS in place, septic abortion—potentially including septicemia, septic shock, and death—may occur; septic abortion typically requires hospitalization and treatment with intravenous antibiotics",
                        "Septic abortion may result in spontaneous abortion or a medical indication for pregnancy termination. Should severe infection of the uterus occur, hysterectomy may be required, which will result in permanent infertility. This device is contraindicated in patients who have had an infected abortion in the prior 3 months"
                    ]
                },
                {
                    "type": "Ovarian cysts:",
                    "description": [
                        "The contraceptive effect of this therapy is mainly due to its local effects within the uterus; therefore, ovulatory cycles with follicular rupture usually occur in patients of fertile age using this therapy",
                        "Most ovarian cysts that occur during use of LNG-releasing IUSs are asymptomatic and disappear spontaneously during two to three months of observation",
                        "Cysts that cause clinical symptoms can result in pelvic or abdominal pain or dyspareunia",
                        "Evaluate persistent ovarian cysts; surgical intervention is not usually required, but may be necessary in some cases, and occurred in 1 (0.06%) of participants in the trial; discuss this risk with patients, as indicated"
                    ]
                },
                {
                    "type": "MRI",
                    "description": [
                        "Safe scanning with MRI may occur under specific conditions",
                        "static magnetic field ≤3 Tesla",
                        "spatial gradient field ≤36,000 Gauss/cm (T/m)",
                        "maximum SAR (whole body) of 4W/kg in first level controlled mode for 15 min"
                    ]
                },
                {
                    "type": "Clinical Considerations for Use and Removal",
                    "description": [
                        "Coagulopathy or use of anticoagulants",
                        "Migraine, focal migraine with asymmetrical visual loss or other symptoms indicating transient cerebral ischemia",
                        "Exceptionally severe headache",
                        "Marked increase of blood pressure",
                        "Severe arterial disease such as stroke or myocardial infarction",
                        "Consider removing device if jaundice or uterine or cervical malignancy occur during use",
                        "Clinical considerations for use and removal",
                        "Obtain a complete medical and social history, including partner status, to determine conditions that might influence the selection of an IUS for contraception",
                        "Exclude underlying endometrial pathology (eg, polyps or cancer) prior to insertion of the device in patients with persistent or uncharacteristic bleeding because irregular bleeding/spotting is common during first months of use and may preclude adequate assessment after insertion.",
                        "Exclude underlying congenital or acquired uterine anomalies, including fibroids, that distort uterine cavity and would be incompatible with correct IUS placement",
                        "Ensure a previously inserted IUS has been removed prior to insertion of the device",
                        "Assess whether the patient is at increased risk of pelvic infection (eg, unprotected sex, history of PID, or acquired immune deficiency syndrome [AIDS]); this therapy does not protect against HIV/STI transmission"
                    ]
                },
                {
                    "type": "Drug interaction overview",
                    "description": [
                        "Drug interactions not studied; drugs or herbal products that induce or inhibit drug metabolizing enzymes, including CYP3A4, may decrease or increase, respectively, the serum concentrations of drug during use; however, contraceptive effect of drug is mediated via direct release of drug into uterine cavity and is unlikely to be affected by drug interactions via enzyme induction or inhibition"
                    ]
                }
            ]
        }
    },
    "interactions": [
        {
            "classification_type": "Serious",
            "interaction_with": "abametapir",
            "description": {
                "common": "abametapir will increase the level or effect of levonorgestrel intrauterine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "antithrombin alfa",
            "description": {
                "common": "levonorgestrel intrauterine, antithrombin alfa.\nEither decreases effects of the other by pharmacodynamic antagonism. Avoid or Use Alternate Drug. Risk of thromboembolic disorders."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "antithrombin III",
            "description": {
                "common": "levonorgestrel intrauterine, antithrombin III.\nEither decreases effects of the other by pharmacodynamic antagonism. Avoid or Use Alternate Drug. Risk of thromboembolic disorders."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "apalutamide",
            "description": {
                "common": "apalutamide will decrease the level or effect of levonorgestrel intrauterine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "argatroban",
            "description": {
                "common": "levonorgestrel intrauterine, argatroban.\nEither decreases effects of the other by pharmacodynamic antagonism. Avoid or Use Alternate Drug. Risk of thromboembolic disorders."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "bemiparin",
            "description": {
                "common": "levonorgestrel intrauterine, bemiparin.\nEither decreases effects of the other by pharmacodynamic antagonism. Avoid or Use Alternate Drug. Risk of thromboembolic disorders."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "bivalirudin",
            "description": {
                "common": "levonorgestrel intrauterine, bivalirudin.\nEither decreases effects of the other by pharmacodynamic antagonism. Avoid or Use Alternate Drug. Risk of thromboembolic disorders."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "cobicistat",
            "description": {
                "common": "cobicistat will increase the level or effect of levonorgestrel intrauterine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "dabrafenib",
            "description": {
                "common": "dabrafenib will decrease the level or effect of levonorgestrel intrauterine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "dalteparin",
            "description": {
                "common": "levonorgestrel intrauterine, dalteparin.\nEither decreases effects of the other by pharmacodynamic antagonism. Avoid or Use Alternate Drug. Risk of thromboembolic disorders."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "elagolix",
            "description": {
                "common": "levonorgestrel intrauterine decreases effects of elagolix by pharmacodynamic antagonism. Avoid or Use Alternate Drug. Based on the mechanism of action of elagolix, estrogen-containing contraceptives are expected to reduce elagolix efficacy. Effects of progestin-only contraceptives on the efficacy of elagolix is unknown. Advise women to use nonhormonal contraceptives during treatment with elagolix and for 1 week after discontinuing elagolix."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "encorafenib",
            "description": {
                "common": "encorafenib will decrease the level or effect of levonorgestrel intrauterine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Coadministration of encorafenib with hormonal contraceptives (CYP3A4 substrates) can result in decreased concentrations and loss of hormonal contraceptive efficacy. Since encorafenib can cause fetal harm, advise women of childbearing potential to use a highly effective nonhormonal contraceptive during treatment and for 2 weeks after final encorafenib dose."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "enoxaparin",
            "description": {
                "common": "levonorgestrel intrauterine, enoxaparin.\nEither decreases effects of the other by pharmacodynamic antagonism. Avoid or Use Alternate Drug. Risk of thromboembolic disorders."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "fondaparinux",
            "description": {
                "common": "levonorgestrel intrauterine, fondaparinux.\nEither decreases effects of the other by pharmacodynamic antagonism. Avoid or Use Alternate Drug. Risk of thromboembolic disorders."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "heparin",
            "description": {
                "common": "levonorgestrel intrauterine, heparin.\nEither decreases effects of the other by pharmacodynamic antagonism. Avoid or Use Alternate Drug. Risk of thromboembolic disorders."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "ivosidenib",
            "description": {
                "common": "ivosidenib will decrease the level or effect of levonorgestrel intrauterine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "lesinurad",
            "description": {
                "common": "lesinurad decreases effects of levonorgestrel intrauterine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Use additional methods of nonhormonal contraception. Do not rely on hormonal contraception alone when taking lesinurad."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "lorlatinib",
            "description": {
                "common": "lorlatinib will decrease the level or effect of levonorgestrel intrauterine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "lumacaftor/ivacaftor",
            "description": {
                "common": "lumacaftor/ivacaftor will decrease the level or effect of levonorgestrel intrauterine by  unspecified interaction mechanism. Avoid or Use Alternate Drug. Avoid coadministration unless benefit outweighs risk.  When coadministered, hormonal contraceptives are not a reliable method of effective birth control. Concomitant use may increase incidence of menstruation associated adverse effects (amenorrhea, dysmenorrhea, menorrhagia)."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "mavacamten",
            "description": {
                "common": "mavacamten will decrease the level or effect of levonorgestrel intrauterine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Progestin and ethinyl estradiol are CYP3A4 substrates. Mavacamten may decrease systemic exposures of ethinyl estradiol and progestin, which may lead to contraceptive failure or an increase in breakthrough bleeding. Advise patients to use a contraceptive method that is not affected by CYP450 enzyme induction (eg, intrauterine system) or add nonhormonal contraception (eg, condoms) during coadministration and for 4 months after last mavacamten dose."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "mifepristone",
            "description": {
                "common": "mifepristone will increase the level or effect of levonorgestrel intrauterine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "nelfinavir",
            "description": {
                "common": "nelfinavir will increase the level or effect of levonorgestrel intrauterine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "omaveloxolone",
            "description": {
                "common": "omaveloxolone will decrease the level or effect of levonorgestrel intrauterine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Omaveloxolone may reduce efficacy of hormonal contraceptives (eg, pill, patch, ring), implants, and progestin-only pills owing to weak CYP3A4 induction."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "perampanel",
            "description": {
                "common": "perampanel will decrease the level or effect of levonorgestrel intrauterine by  unspecified interaction mechanism. Avoid or Use Alternate Drug. Levonorgestrel levels reduced by 40% when coadministered with high dose perampanel (ie, 12 mg/day); effect on other progestins is unknown, consider back up contraception"
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "phenindione",
            "description": {
                "common": "levonorgestrel intrauterine, phenindione.\nEither decreases effects of the other by pharmacodynamic antagonism. Avoid or Use Alternate Drug. Risk of thromboembolic disorders."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "protamine",
            "description": {
                "common": "levonorgestrel intrauterine, protamine.\nEither decreases effects of the other by pharmacodynamic antagonism. Avoid or Use Alternate Drug. Risk of thromboembolic disorders."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "ritonavir",
            "description": {
                "common": "ritonavir will increase the level or effect of levonorgestrel intrauterine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "sugammadex sodium",
            "description": {
                "common": "sugammadex sodium decreases effects of levonorgestrel intrauterine by receptor binding competition. Avoid or Use Alternate Drug. In vitro binding studies showed that sugammadex may bind to progestogen, thereby decreasing progestogen exposure. Therefore, a sugammadex bolus dose is considered to be equivalent to missing dose(s) of hormonal contraceptives containing an estrogen or progestogen. If an oral contraceptive is taken on the same day of sugammadex, or the patient has a transdermal or implant hormonal contraceptive, the patient must use an additional, nonhormonal contraceptive method or back-up method of contraception (eg, condoms and spermicides) for the next 7 days."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "amobarbital",
            "description": {
                "common": "amobarbital will decrease the level or effect of levonorgestrel intrauterine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "atazanavir",
            "description": {
                "common": "atazanavir, levonorgestrel intrauterine. affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Atazanavir may increase or decrease levels of levonorgestrel. Use alternatives if available."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "bosentan",
            "description": {
                "common": "bosentan decreases levels of levonorgestrel intrauterine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "carbamazepine",
            "description": {
                "common": "carbamazepine decreases levels of levonorgestrel intrauterine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "cenobamate",
            "description": {
                "common": "cenobamate will decrease the level or effect of levonorgestrel intrauterine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Increase dose of CYP3A4 substrate, as needed, when coadministered with cenobamate."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ceritinib",
            "description": {
                "common": "ceritinib will increase the level or effect of levonorgestrel intrauterine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "clobazam",
            "description": {
                "common": "clobazam will decrease the level or effect of levonorgestrel intrauterine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Clobazam is a weak CYP3A4 inducer; effectiveness of hormonal contraceptives may be diminished when given concurrently with clobazam. Additional non-hormonal forms of contraception are recommended."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "crofelemer",
            "description": {
                "common": "crofelemer increases levels of levonorgestrel intrauterine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Crofelemer has the potential to inhibit CYP3A4 at concentrations expected in the gut; unlikely to inhibit systemically because minimally absorbed."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "cyclosporine",
            "description": {
                "common": "levonorgestrel intrauterine, cyclosporine.\nEither increases levels of the other by decreasing metabolism. Use Caution/Monitor. Combined oral contraceptives containing EE may inhibit the metabolism and increase plasma concentrations of cyclosporine."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "dexamethasone",
            "description": {
                "common": "dexamethasone decreases levels of levonorgestrel intrauterine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "efavirenz",
            "description": {
                "common": "efavirenz decreases levels of levonorgestrel intrauterine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "enzalutamide",
            "description": {
                "common": "enzalutamide decreases levels of levonorgestrel intrauterine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "eslicarbazepine acetate",
            "description": {
                "common": "eslicarbazepine acetate will decrease the level or effect of levonorgestrel intrauterine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Use additional or alternative nonhormonal birth control."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "etravirine",
            "description": {
                "common": "etravirine decreases levels of levonorgestrel intrauterine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "felbamate",
            "description": {
                "common": "felbamate decreases levels of levonorgestrel intrauterine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "fosphenytoin",
            "description": {
                "common": "fosphenytoin decreases levels of levonorgestrel intrauterine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "griseofulvin",
            "description": {
                "common": "griseofulvin decreases levels of levonorgestrel intrauterine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "insulin degludec",
            "description": {
                "common": "levonorgestrel intrauterine decreases effects of insulin degludec by pharmacodynamic antagonism. Use Caution/Monitor. Progestins may impair glucose tolerance."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "insulin degludec/insulin aspart",
            "description": {
                "common": "levonorgestrel intrauterine decreases effects of insulin degludec/insulin aspart by pharmacodynamic antagonism. Use Caution/Monitor. Progestins may impair glucose tolerance."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "insulin inhaled",
            "description": {
                "common": "levonorgestrel intrauterine decreases effects of insulin inhaled by pharmacodynamic antagonism. Use Caution/Monitor. Progestins may impair glucose tolerance."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "lamotrigine",
            "description": {
                "common": "levonorgestrel intrauterine will decrease the level or effect of lamotrigine by  increasing hepatic clearance. Use Caution/Monitor. Combination oral contraceptives have been shown to significantly decrease plasma concentrations of lamotrigine, likely due to induction of lamotrigine glucuronidation."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "lenacapavir",
            "description": {
                "common": "lenacapavir will increase the level or effect of levonorgestrel intrauterine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Lencapavir may increase CYP3A4 substrates initiated within 9 months after last SC dose of lenacapavir, which may increase potential risk of adverse reactions of CYP3A4 substrates."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "maraviroc",
            "description": {
                "common": "levonorgestrel intrauterine increases levels of maraviroc by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Potential for increased toxicity."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "metformin",
            "description": {
                "common": "levonorgestrel intrauterine decreases effects of metformin by pharmacodynamic antagonism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "mifepristone",
            "description": {
                "common": "mifepristone decreases effects of levonorgestrel intrauterine by pharmacodynamic antagonism. Use Caution/Monitor. Backup contraceptive method recommended."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "mitotane",
            "description": {
                "common": "mitotane will decrease the level or effect of levonorgestrel intrauterine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Monitor; use of nonhormonal contraceptive may be necessary"
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "nafcillin",
            "description": {
                "common": "nafcillin decreases levels of levonorgestrel intrauterine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "nevirapine",
            "description": {
                "common": "nevirapine decreases levels of levonorgestrel intrauterine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "oxcarbazepine",
            "description": {
                "common": "oxcarbazepine decreases levels of levonorgestrel intrauterine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "pentobarbital",
            "description": {
                "common": "pentobarbital decreases levels of levonorgestrel intrauterine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "phenobarbital",
            "description": {
                "common": "phenobarbital decreases levels of levonorgestrel intrauterine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "phenytoin",
            "description": {
                "common": "phenytoin decreases levels of levonorgestrel intrauterine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "primidone",
            "description": {
                "common": "primidone decreases levels of levonorgestrel intrauterine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ribociclib",
            "description": {
                "common": "ribociclib will increase the level or effect of levonorgestrel intrauterine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "rifabutin",
            "description": {
                "common": "rifabutin decreases levels of levonorgestrel intrauterine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "rifampin",
            "description": {
                "common": "rifampin decreases levels of levonorgestrel intrauterine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "rifapentine",
            "description": {
                "common": "rifapentine decreases levels of levonorgestrel intrauterine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "secobarbital",
            "description": {
                "common": "secobarbital will decrease the level or effect of levonorgestrel intrauterine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "St John's Wort",
            "description": {
                "common": "St John's Wort decreases levels of levonorgestrel intrauterine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "teriflunomide",
            "description": {
                "common": "teriflunomide increases levels of levonorgestrel intrauterine by unknown mechanism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "tesamorelin",
            "description": {
                "common": "tesamorelin will decrease the level or effect of levonorgestrel intrauterine by  altering metabolism. Use Caution/Monitor. Use alternative contraception"
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "topiramate",
            "description": {
                "common": "topiramate decreases levels of levonorgestrel intrauterine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "acetazolamide",
            "description": {
                "common": "acetazolamide will increase the level or effect of levonorgestrel intrauterine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "anastrozole",
            "description": {
                "common": "anastrozole will increase the level or effect of levonorgestrel intrauterine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "cyclophosphamide",
            "description": {
                "common": "cyclophosphamide will increase the level or effect of levonorgestrel intrauterine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "larotrectinib",
            "description": {
                "common": "larotrectinib will increase the level or effect of levonorgestrel intrauterine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "levoketoconazole",
            "description": {
                "common": "levoketoconazole will increase the level or effect of levonorgestrel intrauterine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown."
            }
        }
    ],
    "adverse effects": [
        {
            "name": "Unscheduled uterine bleeding",
            "percent": "31.9"
        },
        {
            "name": "Decreased uterine bleeding",
            "percent": "23.4"
        },
        {
            "name": "Abdominal",
            "percent": "22.6"
        },
        {
            "name": "pelvic pain",
            "percent": "18.4"
        },
        {
            "name": "Amenorrhea",
            "percent": "16.3"
        },
        {
            "name": "Headache",
            "percent": "14.9"
        },
        {
            "name": "migraine",
            "percent": "11.9"
        },
        {
            "name": "Genital discharge",
            "percent": "10.5"
        },
        {
            "name": "Increased scheduled uterine bleeding",
            "percent": "8.5"
        },
        {
            "name": "Vulvovaginitis",
            "percent": "7.9"
        },
        {
            "name": "Breast pain",
            "percent": "7.5"
        },
        {
            "name": "Back pain",
            "percent": "6.8"
        },
        {
            "name": "Benign ovarian cyst and associated complications",
            "percent": "6.4"
        },
        {
            "name": "Acne",
            "percent": "6.4"
        },
        {
            "name": "Dysmenorrhea",
            "percent": "3.5"
        },
        {
            "name": "Depression",
            "percent": null
        },
        {
            "name": "depressive mood",
            "percent": null
        },
        {
            "name": "Female genital tract bleeding",
            "percent": null
        },
        {
            "name": "Angioedema",
            "percent": null
        },
        {
            "name": "Cervical perforation",
            "percent": null
        },
        {
            "name": "Failed insertion",
            "percent": null
        },
        {
            "name": "Sepsis",
            "percent": null
        },
        {
            "name": "Uterine bleeding",
            "percent": null
        },
        {
            "name": "Device breakage",
            "percent": null
        },
        {
            "name": "Pulmonary emboli",
            "percent": null
        },
        {
            "name": "Deep vein thrombosis and stroke",
            "percent": null
        },
        {
            "name": "Increased blood pressure",
            "percent": null
        },
        {
            "name": "Arterial thrombotic and venous thromboembolic events",
            "percent": null
        },
        {
            "name": "including cases of pulmonary emboli",
            "percent": null
        },
        {
            "name": "deep vein thrombosis and stroke",
            "percent": null
        },
        {
            "name": "Device breakage",
            "percent": null
        },
        {
            "name": "Hypersensitivity",
            "percent": null
        },
        {
            "name": "eg",
            "percent": null
        },
        {
            "name": "rash",
            "percent": null
        },
        {
            "name": "urticaria and angioedema",
            "percent": null
        },
        {
            "name": "Increased blood pressure",
            "percent": null
        }
    ]
}